Association between ADAMTS13 polymorphisms and risk of cardiovascular events in chronic coronary disease

Thrombosis Research

Volumn 125, Issue 1, 2010, Pages 61-66

  Schettert, Isolmar T ^a   Pereira, Alexandre C ^a   Lopes, Neuza H ^a   Hueb, Whady A ^a   Krieger, Jose E ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

ADAMTS13; Cardiovascular risk factor; Chronic Coronary Disease; MASS II trial; Polymorphism; Von Willebrand

Indexed keywords

ADULT; AGED; ALLELE; ANGINA PECTORIS; ANGIOPLASTY; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEATH; DNA POLYMORPHISM; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HEART INFARCTION; HEART LEFT VENTRICLE; HEART VENTRICLE FUNCTION; HUMAN; INCIDENCE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; REVASCULARIZATION; RISK ASSESSMENT;

ADAM PROTEINS; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; CORONARY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RISK;

EID: 76449114159     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2009.03.008     Document Type: Article

References (40)

1. Bowen D.J., and Collins P.W. Insights into von Willebrand factor proteolysis: clinical implications. Br J Haematol 133 (2006) 457-467
2. Chauhan A.K., Motto D.G., Lamb C.B., Bargemen W., Dockal M., Palomar, et al. Systemic antithrombotic effects of ADAMTS13. J Exp Med 203 (2006) 767-776
3. Kaikita K., Soejima K., Matsukawa M., Nakagaki T., and Ogawa H. Reduced von Willebrand factor-cleaving protease (ADAMTS13) activity in acute myocardial infarction. J Thromb Haemost 4 (2006) 2490-2493
4. Chion C.K., Doggen C.J., Crawley J.T., Lane D.A., and Rosendaal F.R. ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men. Blood 109 5 (2007) 1998-2000
5. Crawley J.T.B., Lane D.A., WoodWard M., Rumley A., and Lowe D.O. Evidence that high von Willebrand factor and low ADAMTS13 levels independently increase the risk of a non-fatal heart attack. J Thromb Haemost 6 (2008) 583-588
6. Kokame K., Matsumoto M., Soejima K., Yagi H., Ishizashi H., Funato M., et al. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci U S A 99 (2002) 11902-11907
7. Donadelli R., Banterla F., Galbusera M., Capoferri C., Bucchioni S., Gastoldi S., et al. In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpura. Thromb Haemost 96 (2006) 454-464
8. Plaimauer B., Fuhrmann J., Mohr G., Wernhart W., Bruno K., Ferrari S., et al. Modulation of ADAMTS13 secretion and specific activity by a combination of common amino acid polymorphisms and a missense mutation. Blood 107 (2006) 118-125
9. Peyvandi F., Lavoretano S., Canciani M., and Manucci P.M. Modulation of the von Willebrand Factor Cleaving Protease (ADAMTS-13) activity by polymorphisms in the ADAMTS-13 gene. J Thromb Haemost 1supplement 1 (july 2003) [Abstract number P0325]
10. Hueb W., Lopes N.H., Gersh B.J., Soares P., Machado L.A., Jatene F.B., et al. Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation 115 (2007) 1082-1089
11. Hueb W., Soares P.R., Gersh B.J., César L.A., Luz P.L., Puig L.B., et al. The Medicine, Angioplasty, or Surgical Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multi-vessel coronary disease: 1-year results. J Am Coll Cardiol 43 (2004) 1743-1751
12. Lopes N.H., Pereira A.C., Hueb W., Soares P.R., Lanz J.R., Gersh B.J., et al. Effect of glycoprotein IIIa PlA2 polymorphism on outcome of patients with stable coronary artery disease and effect of smoking. Am J Cardiol 93 (2004) 1469-1472
13. Schettert I.T., Pereira A.C., Lopes N.H., Hueb W.A., and Krieger J.E. Association between platelet P2Y12 haplotype and risk of cardiovascular events in chronic coronary disease. Thromb Res 118 (2006) 679-683
14. Sauer S., Lechner D., Berlin K., Lehrach H., Escary J.L., Fox N., et al. A novel procedure for efficient genotyping of single nucleotide polymorphisms. Nucleic Acids Res 28 (2000) E13
15. Levy G.G., Nichols W.C., Lian E.C., Foroud T., McClintick J.N., McGee B.M., et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413 (2001) 488-494
16. Wigginton J.E., Cutler D.J., and Abecasis G.R. A note on exact tests of Hardy-Weinberg equilibrium. Am J Hum Genet 76 (2005) 887-893
17. Zhao L.P., Li S., and Khalid N. Assessing Haplotype-Based Association with Multiple SNPs in Case-Control Studies. Am J Hum Genet 72 (2003) 1231-1250
18. Watkins H., and Farrall M. Genetic susceptibility to coronary artery disease: from promise to progress. Nat Rev Genet 7 (2006) 163-173
19. Topol E.J., Smith J., Plow E.F., and Wang Q.K. Genetic susceptibility to myocardial infarction and coronary artery disease. Hum Mol Genet 15 (2006) R117-R123
20. Whincup P.H., Danesh J., Walker M., Lennon L., Thomson A., Appleby P., et al. von Willebrand factor and coronary heart disease: prospective study and meta-analysis. Eur Heart J 23 (2002) 1764-1770
21. Martinelli I. von Willebrand factor and factor VIII as risk factors for arterial and venous thrombosis. Semin Hematol 42 (2005) 49-55
22. Dong J.F., Moake J.L., Nolasco L., Bernardo A., Arceneaux W., Shrimpton C.N., et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 100 12 (2002) 4033-4039
23. Shida Y., Nishio K., Sugimoto M., Mizuno M., Hamada M., Kato S., et al. Functional imaging of shear-dependent activity of ADAMTS13 in regulating mural thrombus growth under whole blood flow conditions. Blood 111 (2008) 1295-1298
24. Feys H.B., Canciani M.T., Peyvandi F., Dckmyn H., Vanhoorelbeke K., Mannucci P.M., et al. ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis. Br J Haematol 138 (2007) 534-540
25. Hoshiba Y., Hatakeyama K., Tanabe T., Asada Y., Goto S., et al. Co-localization of von Willebrand factor with platelet thrombi, tissue factor and platelets with fibrin, and consistent presence of inflammatory cells in coronary thrombi obtained by an aspiration device from patients with acute myocardial infarction. J Thromb Haemost 4 (2006) 114-120
26. Matsukawa M., Kaikita K., Soejima K., Fuchigami S., Nakamura Y., Honda T., et al. Serial changes in von Willebrand factor-cleaving protease (ADAMTS13) and prognosis after acute myocardial infarction. Am J Cardiol 100 (2007) 758-763
27. Fuchigami S., Kaikita K., Soejima K., Matsukawa M., Honda T., Tsujita K., et al. Changes in plasma Von Willebrand factor-cleaving protease (ADAMTS13) levels in patients with unstable angina. Thromb Res 122 5 (2008) 618-623
28. Kokame K., and Miyata T. Genetic defects leading to hereditary thrombotic thrombocytopenic purpura. Semin Hematol 41 1 (2004) 34-40
29. Tao Z., Anthony K., Peng Y., Choi H., Nolasco L., Rice L., et al. Novel ADAMTS-13 mutations in an adult with delayed onset thrombotic thrombocytopenic purpura. J Thromb Haemost 4 9 (2006) 1931-1935
30. Zheng X., Chung D., Takayama T.K., Majerus E.M., Sadler J.E., and Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 276 (2001) 41059-41063
31. Zanardelli S., Crawley J.T., Chion C.K., Lam J.K., Preston R.J., and Lane D.A. ADAMTS13 substrate recognition of von Willebrand factor A2 domain. J Biol Chem 281 (2006) 1555-1563
32. Nicholson A.C., Malik S.B., Logsdon J.M., and Van Meir E.G. Functional evolution of ADAMTS genes: evidence from analyses of phylogeny and gene organization. BMC Evol Biol 5 1 (2005) 11
33. Bongers T.N., Maat M.P.M., Dippel D.W.J., Uitterlinden A.G., and Leebeek F.W. Absence of Pro475Ser polymorphism in ADAMTS-13 in Caucasians. J Thromb Haemost 3 (2005) 805
34. International Hapmap project. http://www.hapmap.org. Accessed October, 08, 2008.
35. Seattle SNP project. http://pga.gs.washington.edu/. Accessed October, 08, 2008.
36. Merikangas K.R., Low N.C., and Hardy J. Understanding sources of complexity in chronic diseases-the importance of integration of genetics and epidemiology. Int J Epidemiol 35 (2006) 590-592
37. Ford E.S., Ajani U.A., Croft J.B., Critchley J.A., Labarthe D.R., Kottke T.E., et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med 356 (2007) 2388-2398
38. Unal B., Critchley J.A., and Capewell S. Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000. Circulation 109 (2004) 1101-1107
39. Yusuf S., Fallen E., Harrington R.A., Guyton R.A., et al. Clinical decisions. Management of stable coronary disease. N Engl J Med 357 17 (2007) 1762-1766
40. Arnett D.K., Baird A.E., Barkley R.A., Basson C.T., Boerwinkle E., Ganesh S.K., et al. Relevance of genetics and genomics for prevention and treatment of cardiovascular disease: a scientific statement from the American Heart Association Council on Epidemiology and Prevention, the Stroke Council, and the Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 115 (2007) 2878-2901